Immunotherapy given during and after chemoradiation did not improve survival for study participants with limited-stage, small-cell lung cancer (SCLC) according to the results of an international ...

Platinum-based chemotherapy, when administered before chemoradiotherapy, improved progression-free and overall survival for patients with locally advanced cervical cancer. Patients with locally ...

Adding immunotherapy to chemoradiation therapy (CRT) for limited-stage small cell lung cancer (SCLC) failed to improve survival in a randomized trial. As compared with CRT alone, concurrent ...

The findings on tumor mutational burden (TMB) may fill a gap in biomarkers for patients who have non–small cell lung cancer (NSCLC). The findings could make it easier for clinicians to personalize ...

Treatment with Tagrisso after chemoradiation resulted in patients with EGFR-mutant stage 3 non-small cell lung cancer being nearly three times less likely to experience disease progression when ...

Please provide your email address to receive an email when new articles are posted on . “Interest in organ preservation strategies for patients with rectal cancer persists,” Paul B. Romesser, MD, ...

WASHINGTON — Reduced doses of radiation therapy and immunotherapy did not work as well as the standard chemoradiation for early-stage HPV-associated oropharyngeal cancer, in a new study. These ...

Please provide your email address to receive an email when new articles are posted on . “In patients with [isocitrate dehydrogenase (IDH)] wild-type glioblastoma, epileptic seizures are common during ...

Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial Patients with medically inoperable and/or ...

An early-phase, dose-escalation study of a hypofractionated approach to concurrent chemoradiation using an an adaptive stereotactic ablative radiotherapy (SABR) boost showed promising results in ...

A bladder-specific 15-gene transcriptomic signature distinguishes patients with MIBC at high risk for poor chemoradiation therapy outcomes. A 15-gene transcriptomic signature has the potential to ...